Investment Thesis — IDEXX Laboratories, Inc.
The market is mispricing the extreme technical setup in IDEXX, where an unprecedented short interest (298% of float) creates a powder keg for a violent short squeeze. While consensus focuses on premium valuation and potential growth deceleration, the underlying resilience of pet healthcare and the technical overhang are being overlooked.
Catalysts
- Strong Q1/Q2 2024 earnings beat, demonstrating resilience in pet care spending.
- Announcement of new diagnostic innovations or expanded market penetration.
- Significant reduction in short interest (indicating covering) or a widely publicized short squeeze event.
Risk Factors
- Sustained slowdown in discretionary pet care spending due to economic pressures.
- Increased competition from new entrants or existing players eroding market share/pricing power.
- Regulatory changes impacting diagnostic testing or veterinary practices.
Key Debates
IDXX's 43.57x P/E holds through FY25 despite 8.7% growth.
IDXX reaches 784.38 analyst PT by mid-2025 reversing 20d -9% drop.
IDXX sustains 8.7% revenue growth through H1 2025.